Breast cancer is one of the most common and deadly types of cancer. Everyday, researchers are coming up with new and improved ways to attempt to treat this deadly disease. Often times the best solution is the one that isn’t so obvious. Dariusz Smilowitcz with Mol. Pharmaceutics took his knowledge of Inorganic chemistry and paired it with biology to find a metal-based drug candidate to attempt to utilize peptides to increase selectivity of organometallic compounds . Cell-targeting peptides are increasingly being used in the field of cancer. Smilowitcz and lab were motivated by the activity of gold complexes for the treatment of various diseases. They predicted that gold peptide bioconjugates would be interesting candidates for breast cancer therapies. After several biological reactions, they found that in vitro data showed that the gold bioconjugate exhibited improved activity compared to the parent gold compound. In addition the gold bioconjugate had excellent targeting properties which supported the idea that the Au peptide conjugate exhibited 10 times lower cytotoxic activity. 
To find out more of the specifics of this research feel free to read the paper published in the acs journal!!
- Smilowicz D.; Slootweg J. C; Metzler-Nolte N. Bioconjugation of Cyclometalated Gold(III) Lipoic Acid Fragments to Linear and Cyclic Breast Cancer Targeting Peptides. Mol. Pharmaceutics. 2019, 16, 11, 4572-4581